This post was originally published on this site

After more than 20 years in the industry, Ivana Magovčević-Liebisch had done it all — except build a company from scratch. Then Bruce Booth at Atlas Venture mentioned a couple of TREM2 assets he was trying to snag from Amgen’s old neuroscience pipeline. Read more.

The post Vigil Neuroscience launches with a $50M Series A and two former Amgen neuroscience candidates appeared first on Atlas Venture.